Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6403567 | ASTELLAS | N-pyrazole A2A adenosine receptor agonists |
Apr, 2022
(11 months ago) | |
US8106183 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE47301 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(3 years from now) |
Market Authorisation Date: 10 April, 2008
Treatment: Method for stimulating coronary vasodilation for purposes of imaging the heart
Dosage: SOLUTION;INTRAVENOUS
11
United States
3
Japan
2
Korea, Republic of
2
Canada
2
China
2
European Union
1
Portugal
1
Slovenia
1
Hong Kong
1
Israel
1
New Zealand
1
Poland
1
Australia
1
Norway
1
Russia
1
Mexico
1
South Africa
1
Spain
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic